Delisting riskPopularity #4,622
Vaxart (VXRT)
Clinical-stage biotech developing oral tablet vaccines for infectious disease.
$0.4699
After hours−0.01 (−1.07%)
At close$0.4750(−1.06%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 0.03% | 64.7K shares | |
|---|---|---|---|
| 5 holders · as of Jun 30, 2026 | |||
| Insiders | 3.19% | 7.75M shares | |
| 12 holders · as of Jul 20, 2026 | |||
| Other | 96.78% | 235.02M shares | |
| remainder | |||
242.84M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
5 holders · 64.7K shares · 3 new positions · 3 increased · 0 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Heritage Wealth Advisors | 29.7K | 0.01% | +29.7Knew | Aug 14, 2026 |
| LVM Capital Management Ltd/MI | 25.0K | 0.01% | 0 | Jul 9, 2026 |
| Kingswood Wealth Advisors, LLC | 10.0K | 0.00% | +10.0K | Jul 27, 2026 |
| Archer Investment Corp | 15 | 0.00% | 0 | Aug 19, 2026 |
| Strive Financial Group ,LLC | 2 | 0.00% | +2new | Aug 4, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 22, 2026 | W. Mark Watsondirector | Purchase | 10,000 | $0.6530 | 134,125 |
| Nov 17, 2025 | W. Mark Watsondirector | Purchase · 2 lots | 20,000 | $0.4093 | 124,125 |
| Nov 17, 2025 | Elaine J. Herondirector | Purchase · 2 lots | 40,000 | $0.3980 | 96,566 |
House and Senate disclosures
Not reported.
